Three-dimensional perfused human in vitro model of non-alcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 23, Issue 2, 2017, Pages 204-215

  Kostrzewski, Tomasz ^a   Cornforth, Terri ^a   Snow, Sophie A ^a   Ouro Gnao, Larissa ^a   Rowe, Cliff ^a   Large, Emma M ^a   Hughes, David J ^a  

^a Centre for Innovation and Enterprise   (United Kingdom)

Author keywords

Fatty liver; Hepatocytes; Liver disease; Non alcoholic fatty liver disease; Organ on chip; Primary cell culture; Three dimensional cell culture

Indexed keywords

ADIPOCYTOKINE; ALBUMIN; CHOLESTEROL 7ALPHA MONOOXYGENASE; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; FATTY ACID; FATTY ACID BINDING PROTEIN; FATTY ACID BINDING PROTEIN 3; METFORMIN; PIOGLITAZONE; PROTEOME; SOMATOMEDIN BINDING PROTEIN 1; UNCLASSIFIED DRUG; AZO COMPOUND; COLORING AGENT; CYP2C9 PROTEIN, HUMAN; CYP3A4 PROTEIN, HUMAN; CYP7A1 PROTEIN, HUMAN; IGFBP1 PROTEIN, HUMAN; OIL RED O; TRIACYLGLYCEROL;

ARTICLE; CELL METABOLISM; CONTROLLED STUDY; CULTURE MEDIUM; CYTOKINE RELEASE; CYTOTOXICITY; FAT LOADING; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID TRANSPORT; LIVER CELL CULTURE; LIVER FUNCTION; NONALCOHOLIC FATTY LIVER; PHENOTYPE; PROCEDURES CONCERNING CELLS; QUANTITATIVE ANALYSIS; UPREGULATION; ADIPOCYTE; BIOLOGICAL MODEL; BIOREACTOR; CELL CULTURE TECHNIQUE; CRYOPRESERVATION; ENZYMOLOGY; LIVER CELL; METABOLISM; PERFUSION; PRECLINICAL STUDY; PRIMARY CELL CULTURE; PROCEDURES; TISSUE SCAFFOLD;

ADIPOCYTES; ADIPOKINES; AZO COMPOUNDS; BIOREACTORS; CELL CULTURE TECHNIQUES; CHOLESTEROL 7-ALPHA-HYDROXYLASE; COLORING AGENTS; CRYOPRESERVATION; CYTOCHROME P-450 CYP2C9; CYTOCHROME P-450 CYP3A; DRUG EVALUATION, PRECLINICAL; FATTY ACIDS, NONESTERIFIED; HEPATOCYTES; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 1; MODELS, BIOLOGICAL; NON-ALCOHOLIC FATTY LIVER DISEASE; PERFUSION; PRIMARY CELL CULTURE; TISSUE SCAFFOLDS; TRIGLYCERIDES;

EID: 85009216250     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v23.i2.204     Document Type: Article

References (58)

1. Moore JB. Non-alcoholic fatty liver disease: the hepatic consequence of obesity and the metabolic syndrome. Proc Nutr Soc 2010; 69: 211-220 [PMID: 20158939 DOI: 10.1017/S0029665110000030]
2. Than NN, Newsome PN. A concise review of non-alcoholic fatty liver disease. Atherosclerosis 2015; 239: 192-202 [PMID: 25617860 DOI: 10.1016/j.atherosclerosis.2015.01.001]
3. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152 [PMID: 15254578 DOI: 10.1172/JCI22422]
4. Donato MT, Lahoz A, Jiménez N, Pérez G, Serralta A, Mir J, Castell JV, Gómez-Lechón MJ. Potential impact of steatosis on cytochrome P450 enzymes of human hepatocytes isolated from fatty liver grafts. Drug Metab Dispos 2006; 34: 1556-1562 [PMID: 16763015 DOI: 10.1124/dmd.106.009670]
5. Lake AD, Novak P, Fisher CD, Jackson JP, Hardwick RN, Billheimer DD, Klimecki WT, Cherrington NJ. Analysis of global and absorption, distribution, metabolism, and elimination gene expression in the progressive stages of human nonalcoholic fatty liver disease. Drug Metab Dispos 2011; 39: 1954-1960 [PMID: 21737566 DOI: 10.1124/dmd.111.040592]
6. Sanches SC, Ramalho LN, Augusto MJ, da Silva DM, Ramalho FS. Nonalcoholic Steatohepatitis: A Search for Factual Animal Models. Biomed Res Int 2015; 2015: 574832 [PMID: 26064924 DOI: 10.1155/2015/574832]
7. Willebrords J, Pereira IV, Maes M, Crespo Yanguas S, Colle I, Van Den Bossche B, Da Silva TC, de Oliveira CP, Andraus W, Alves VA, Cogliati B, Vinken M. Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res 2015; 59: 106-125 [PMID: 26073454 DOI: 10.1016/j.plipres.2015.05.002]
8. Chavez-Tapia NC, Rosso N, Tiribelli C. In vitro models for the study of non-alcoholic fatty liver disease. Curr Med Chem 2011; 18: 1079-1084 [PMID: 21254970]
9. Cui W, Chen SL, Hu KQ. Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am J Transl Res 2010; 2: 95-104 [PMID: 20182586]
10. Vidyashankar S, Sharath Kumar LM, Barooah V, Sandeep Varma R, Nandakumar KS, Patki PS. Liv.52 up-regulates cellular antioxidants and increase glucose uptake to circumvent oleic acid induced hepatic steatosis in HepG2 cells. Phytomedicine 2012; 19: 1156-1165 [PMID: 22940028 DOI: 10.1016/j.phymed.2012.08.005]
11. Chavez-Tapia NC, Rosso N, Tiribelli C. Effect of intracellular lipid accumulation in a new model of non-alcoholic fatty liver disease. BMC Gastroenterol 2012; 12: 20 [PMID: 22380754 DOI: 10.1186/1471-230X-12-20]
12. Janorkar AV, Harris LM, Murphey BS, Sowell BL. Use of threedimensional spheroids of hepatocyte-derived reporter cells to study the effects of intracellular fat accumulation and subsequent cytokine exposure. Biotechnol Bioeng 2011; 108: 1171-1180 [PMID: 21449029 DOI: 10.1002/bit.23025]
13. Donato MT, Lahoz A, Castell JV, Gómez-Lechón MJ. Cell lines: a tool for in vitro drug metabolism studies. Curr Drug Metab 2008; 9: 1-11 [PMID: 18220566]
14. Olsavsky KM, Page JL, Johnson MC, Zarbl H, Strom SC, Omiecinski CJ. Gene expression profiling and differentiation assessment in primary human hepatocyte cultures, established hepatoma cell lines, and human liver tissues. Toxicol Appl Pharmacol 2007; 222: 42-56 [PMID: 17512962 DOI: 10.1016/j.taap.2007.03.032]
15. Alexopoulos LG, Saez-Rodriguez J, Cosgrove BD, Lauffenburger DA, Sorger PK. Networks inferred from biochemical data reveal profound differences in toll-like receptor and inflammatory signaling between normal and transformed hepatocytes. Mol Cell Proteomics 2010; 9: 1849-1865 [PMID: 20460255 DOI: 10.1074/mcp.M110.000406]
16. Dash A, Inman W, Hoffmaster K, Sevidal S, Kelly J, Obach RS, Griffith LG, Tannenbaum SR. Liver tissue engineering in the evaluation of drug safety. Expert Opin Drug Metab Toxicol 2009; 5: 1159-1174 [PMID: 19637986 DOI: 10.1517/17425250903160664]
17. Gómez-Lechón MJ, Donato MT, Martínez-Romero A, Jiménez N, Castell JV, O'Connor JE. A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 2007; 165: 106-116 [PMID: 17188672 DOI: 10.1016/j.cbi.2006.11.004]
18. Joshi-Barve S, Barve SS, Amancherla K, Gobejishvili L, Hill D, Cave M, Hote P, McClain CJ. Palmitic acid induces production of proinflammatory cytokine interleukin-8 from hepatocytes. Hepatology 2007; 46: 823-830 [PMID: 17680645 DOI: 10.1002/hep.21752]
19. Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organson-chips. Trends Cell Biol 2011; 21: 745-754 [PMID: 22033488 DOI: 10.1016/j.tcb.2011.09.005]
20. Ebrahimkhani MR, Neiman JA, Raredon MS, Hughes DJ, Griffith LG. Bioreactor technologies to support liver function in vitro. Adv Drug Deliv Rev 2014; 69-70: 132-157 [PMID: 24607703 DOI: 10.1016/j.addr.2014.02.011]
21. Lin C, Ballinger KR, Khetani SR. The application of engineered liver tissues for novel drug discovery. Expert Opin Drug Discov 2015; 10: 519-540 [PMID: 25840592 DOI: 10.1517/17460441.201 5.1032241]
22. Esch EW, Bahinski A, Huh D. Organs-on-chips at the frontiers of drug discovery. Nat Rev Drug Discov 2015; 14: 248-260 [PMID: 25792263 DOI: 10.1038/nrd4539]
23. Sarkar U, Rivera-Burgos D, Large EM, Hughes DJ, Ravindra KC, Dyer RL, Ebrahimkhani MR, Wishnok JS, Griffith LG, Tannenbaum SR. Metabolite profiling and pharmacokinetic evaluation of hydrocortisone in a perfused three-dimensional human liver bioreactor. Drug Metab Dispos 2015; 43: 1091-1099 [PMID: 25926431 DOI: 10.1124/dmd.115.063495]
24. Domansky K, Inman W, Serdy J, Dash A, Lim MH, Griffith LG. Perfused multiwell plate for 3D liver tissue engineering. Lab Chip 2010; 10: 51-58 [PMID: 20024050 DOI: 10.1039/b913221j]
25. Vivares A, Salle-Lefort S, Arabeyre-Fabre C, Ngo R, Penarier G, Bremond M, Moliner P, Gallas JF, Fabre G, Klieber S. Morphological behaviour and metabolic capacity of cryopreserved human primary hepatocytes cultivated in a perfused multiwell device. Xenobiotica 2015; 45: 29-44 [PMID: 25068923 DOI: 10.3109/00498254.2014.944612]
26. Fitzpatrick E, Dhawan A. Noninvasive biomarkers in nonalcoholic fatty liver disease: current status and a glimpse of the future. World J Gastroenterol 2014; 20: 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851]
27. Wruck W, Kashofer K, Rehman S, Daskalaki A, Berg D, Gralka E, Jozefczuk J, Drews K, Pandey V, Regenbrecht C, Wierling C, Turano P, Korf U, Zatloukal K, Lehrach H, Westerhoff HV, Adjaye J. Multi-omic profiles of human non-alcoholic fatty liver disease tissue highlight heterogenic phenotypes. Sci Data 2015; 2: 150068 [PMID: 26646939 DOI: 10.1038/sdata.2015.68]
28. Fisher CD, Lickteig AJ, Augustine LM, Ranger-Moore J, Jackson JP, Ferguson SS, Cherrington NJ. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos 2009; 37: 2087-2094 [PMID: 19651758 DOI: 10.1124/dmd.109.027466]
29. Donato MT, Jiménez N, Serralta A, Mir J, Castell JV, Gómez-Lechón MJ. Effects of steatosis on drug-metabolizing capability of primary human hepatocytes. Toxicol In Vitro 2007; 21: 271-276 [PMID: 16950596 DOI: 10.1016/j.tiv.2006.07.008]
30. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptindeficient mice. Nat Med 2000; 6: 998-1003 [PMID: 10973319 DOI: 10.1038/79697]
31. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, Austin AS, Freeman JG, Morgan L, Webber J. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008; 135: 1176-1184 [PMID: 18718471 DOI: 10.1053/j.gastro.2008.06.047]
32. Puri P, Baillie RA, Wiest MM, Mirshahi F, Choudhury J, Cheung O, Sargeant C, Contos MJ, Sanyal AJ. A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology 2007; 46: 1081-1090 [PMID: 17654743 DOI: 10.1002/hep.21763]
33. Araya J, Rodrigo R, Videla LA, Thielemann L, Orellana M, Pettinelli P, Poniachik J. Increase in long-chain polyunsaturated fatty acid n - 6/n - 3 ratio in relation to hepatic steatosis in patients with non-alcoholic fatty liver disease. Clin Sci (Lond) 2004; 106: 635-643 [PMID: 14720121 DOI: 10.1042/CS20030326]
34. Lu Y, Zhang G, Shen C, Uygun K, Yarmush ML, Meng Q. A novel 3D liver organoid system for elucidation of hepatic glucose metabolism. Biotechnol Bioeng 2012; 109: 595-604 [PMID: 22006574 DOI: 10.1002/bit.23349]
35. Shulman M, Nahmias Y. Long-term culture and coculture of primary rat and human hepatocytes. Methods Mol Biol 2013; 945: 287-302 [PMID: 23097113 DOI: 10.1007/978-1-62703-125-7-17]
36. Amaro A, Fabbrini E, Kars M, Yue P, Schechtman K, Schonfeld G, Klein S. Dissociation between intrahepatic triglyceride content and insulin resistance in familial hypobetalipoproteinemia. Gastroenterology 2010; 139: 149-153 [PMID: 20303351 DOI: 10.1053/j.gastro.2010.03.039]
37. Bae JC, Seo SH, Hur KY, Kim JH, Lee MS, Lee MK, Lee WY, Rhee EJ, Oh KW. Association between Serum Albumin, Insulin Resistance, and Incident Diabetes in Nondiabetic Subjects. Endocrinol Metab (Seoul) 2013; 28: 26-32 [PMID: 24396647 DOI: 10.3803/EnM.2013.28.1.26]
38. Ishizaka N, Ishizaka Y, Nagai R, Toda E, Hashimoto H, Yamakado M. Association between serum albumin, carotid atherosclerosis, and metabolic syndrome in Japanese individuals. Atherosclerosis 2007; 193: 373-379 [PMID: 16904116 DOI: 10.1016/j.atherosclero sis.2006.06.031]
39. Fierbinteanu-Braticevici C, Baicus C, Tribus L, Papacocea R. Predictive factors for nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD). J Gastrointestin Liver Dis 2011; 20: 153-159 [PMID: 21725512]
40. Aubert J, Begriche K, Knockaert L, Robin MA, Fromenty B. Increased expression of cytochrome P450 2E1 in nonalcoholic fatty liver disease: mechanisms and pathophysiological role. Clin Res Hepatol Gastroenterol 2011; 35: 630-637 [PMID: 21664213 DOI: 10.1016/j.clinre.2011.04.015]
41. Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease. J Hepatol 2013; 58: 395-398 [PMID: 22940046 DOI: 10.1016/j.jhep.2012.08.018]
42. Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 1-28 [PMID: 16406828 DOI: 10.1016/j.mito.2005.10.004]
43. Min HK, Kapoor A, Fuchs M, Mirshahi F, Zhou H, Maher J, Kellum J, Warnick R, Contos MJ, Sanyal AJ. Increased hepatic synthesis and dysregulation of cholesterol metabolism is associated with the severity of nonalcoholic fatty liver disease. Cell Metab 2012; 15: 665-674 [PMID: 22560219 DOI: 10.1016/j.cmet.2012.04.004]
44. Li HH, Doiron K, Patterson AD, Gonzalez FJ, Fornace AJ. Identification of serum insulin-like growth factor binding protein 1 as diagnostic biomarker for early-stage alcohol-induced liver disease. J Transl Med 2013; 11: 266 [PMID: 24152801 DOI: 10.11 86/1479-5876-11-266]
45. Tao R, Xiong X, Harris RA, White MF, Dong XC. Genetic inactivation of pyruvate dehydrogenase kinases improves hepatic insulin resistance induced diabetes. PLoS One 2013; 8: e71997 [PMID: 23940800 DOI: 10.1371/journal.pone.0071997]
46. Anstee QM, Day CP. The genetics of NAFLD. Nat Rev Gastroenterol Hepatol 2013; 10: 645-655 [PMID: 24061205 DOI: 10.1038/nrgastro.2013.182]
47. Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18: 727-735 [PMID: 22371632 DOI: 10.3748/wjg.v18.i8.727]
48. Akyildiz M, Gunsar F, Nart D, Sahin O, Yilmaz F, Akay S, Ersoz G, Karasu Z, Ilter T, Batur Y, Berdeli A, Akarca U. Macrophage migration inhibitory factor expression and MIF gene -173 G/C polymorphism in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2010; 22: 192-198 [PMID: 19829123 DOI: 10.1097/MEG.0b013e328331a596]
49. Morrison MC, Kleemann R. Role of Macrophage Migration Inhibitory Factor in Obesity, Insulin Resistance, Type 2 Diabetes, and Associated Hepatic Co-Morbidities: A Comprehensive Review of Human and Rodent Studies. Front Immunol 2015; 6: 308 [PMID: 26124760 DOI: 10.3389/fimmu.2015.00308]
50. Paschos P, Paletas K. Non alcoholic fatty liver disease and metabolic syndrome. Hippokratia 2009; 13: 9-19 [PMID: 19240815]
51. Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: From physiopathology to therapy. J Hepatol 2016; 64: 1403-1415 [PMID: 26867490 DOI: 10.1016/j.jhep.2016.02.004]
52. Hardy T, Anstee QM, Day CP. Nonalcoholic fatty liver disease: new treatments. Curr Opin Gastroenterol 2015; 31: 175-183 [PMID: 25774446 DOI: 10.1097/MOG.0000000000000175]
53. Qin S, Liu T, Kamanna VS, Kashyap ML. Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-alpha. Arterioscler Thromb Vasc Biol 2007; 27: 2428-2434 [PMID: 17872455 DOI: 10.1161/ATVBAHA.107.150193]
54. Sakamoto J, Kimura H, Moriyama S, Odaka H, Momose Y, Sugiyama Y, Sawada H. Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone. Biochem Biophys Res Commun 2000; 278: 704-711 [PMID: 11095972 DOI: 10.1006/bbrc.2000.3868]
55. Nagashima K, Lopez C, Donovan D, Ngai C, Fontanez N, Bensadoun A, Fruchart-Najib J, Holleran S, Cohn JS, Ramakrishnan R, Ginsberg HN. Effects of the PPARgamma agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus. J Clin Invest 2005; 115: 1323-1332 [PMID: 15841215 DOI: 10.1172/JCI23219]
56. Semple RK, Chatterjee VK, O'Rahilly S. PPAR gamma and human metabolic disease. J Clin Invest 2006; 116: 581-589 [PMID: 16511590 DOI: 10.1172/JCI28003]
57. Liu F, Wang C, Zhang L, Xu Y, Jang L, Gu Y, Cao X, Zhao X, Ye J, Li Q. Metformin prevents hepatic steatosis by regulating the expression of adipose differentiation-related protein. Int J Mol Med 2014; 33: 51-58 [PMID: 24253218 DOI: 10.3892/ijmm.2013.1560]
58. Federico A, Zulli C, de Sio I, Del Prete A, Dallio M, Masarone M, Loguercio C. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20: 16841-16857 [PMID: 25492998 DOI: 10.3748/wjg.v20. i45.16841]